US50127T1097 - Common Stock
KURA ONCOLOGY INC
NASDAQ:KURA (4/18/2024, 7:04:36 PM)
After market: 17.68 0 (0%)17.68
-0.31 (-1.72%)
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. The company is headquartered in San Diego, California and currently employs 131 full-time employees. The company went IPO on 2015-11-05. The firm is engaged in the discovery and development of medicines for the treatment of cancer. The Company’s pipeline consists of small molecule product candidates that target cancer signaling pathways. The Company’s products candidate includes Ziftomenib, Tipifarnib, and KO-2806. The Ziftomenib is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene for the treatment of genetically defined acute myeloid leukemia (AML) patients. Tipifarnib is a potent, selective and orally bioavailable inhibitor of farnesyl transferase. KO-2806, is a next generation farnesyl transferase inhibitor (FTI), which it demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.
KURA ONCOLOGY INC
12730 High Bluff Drive, Suite 400
San Diego CALIFORNIA 92130
P: 18585008800
CEO: Troy E. Wilson
Employees: 131
Website: https://www.kuraoncology.com/
SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the...
SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to...
These stocks are moving in today's after hours session
– Company anticipates dosing of KO-2806 in combination with adagrasib in KRASG12C-mutant NSCLC next quarter – – Dose escalation of KO-2806 as a...
SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to...
Kura Oncology reported Q4 2023 financial results, stating a GAAP EPS of -$0.55.
Here you can normally see the latest stock twits on KURA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: